Favipiravir

Status
Phase 2
Condition
COVID-19
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Favipiravir  is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses.

Study Purpose

The objective of this study is to evaluate the efficacy of oral favipiravir compared with SOC in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >